Is motor reserve associated with a rapid progression of Parkinson disease?

Myung Jun Lee1, Kyoungjune Pak2, Jae-Hyeok Lee3

  • 1Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, Republic of Korea.

PubMed

Insights

Motor reserve estimates (MRes) independently predict faster motor decline and increased risk of Hoehn & Yahr stage 3 progression in Parkinson's disease (PD). This finding clarifies the independent effect of motor reserve on clinical outcomes.

Area of Science:

  • Neurology
  • Neuroscience
  • Biomedical Engineering

Background:

  • Motor reserve estimates (MRes) derived from residual approaches correlate with motor severity in Parkinson's disease (PD).
  • The independent effect of motor reserve on clinical outcomes in PD remains unclear.

Purpose of the Study:

  • To investigate the independent influence of motor reserve on the long-term outcome of Parkinson's disease.
  • To assess the association of MRes with motor severity progression and phenoconversion risk.

Main Methods:

  • Utilized Parkinson's Progression Markers Initiative (PPMI) and Pusan National University Hospital (PNUH) datasets.
  • Calculated two MRes types: original and modified, based on putaminal dopamine transporter (DAT) levels and motor severity.
  • Employed linear mixed-effect models and Kaplan-Meier plots to analyze MRes association with motor progression and Hoehn & Yahr (H&Y) stage 3 risk.

Main Results:

  • Modified MRes, unlike original MRes, did not correlate with baseline motor scores.
  • Modified MRes in both cohorts were significantly associated with a rapid increase in motor severity over time.
  • High modified MRes levels indicated a higher risk of progression to H&Y stage 3 in both patient groups.

Conclusions:

  • Motor reserve estimates (MRes) are independently associated with accelerated motor deterioration in Parkinson's disease.
  • Higher MRes predict an increased risk of progressing to Hoehn & Yahr stage 3, independent of baseline motor severity.